Phase 2b Biomarker Analysis: BCMA CAR-T in Myasthenia Gravis

from TheBrief.Health · host TheBrief.Health

BCMA-directed CAR-T therapy shows promise in myasthenia gravis by selectively targeting plasma cells, improving outcomes, and prompting biomarker-guided care, outpatient delivery models, and health system adaptation.

Episode metadata supplied by the publisher feed · Published Apr 16, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Phase 2b Biomarker Analysis: BCMA CAR-T in Myasthenia Gravis

0:00 1:42

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 1 minute long.

When was this TheBrief.Health episode published?

This episode was published on April 16, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!